These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 32338548)

  • 1. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
    Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
    Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
    [No Abstract]   [Full Text] [Related]  

  • 2. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
    Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence of brigatinib as second-line treatment after crizotinib for ALK+ non-small cell lung cancer using South Korean claims data (K-AREAL).
    Lee JE; Nam JH; Kwon SH; Kim BK; Ha SM
    Cancer Med; 2024 Jul; 13(14):e70030. PubMed ID: 39030811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brigatinib in
    Heredia D; Barrón F; Cardona AF; Campos S; Rodriguez-Cid J; Martinez-Barrera L; Alatorre J; Salinas MÁ; Lara-Mejia L; Flores-Estrada D; Arrieta O
    Future Oncol; 2021 Jan; 17(2):169-181. PubMed ID: 32986959
    [No Abstract]   [Full Text] [Related]  

  • 6. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
    Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
    Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Naito T; Shiraishi H; Fujiwara Y
    Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X; Zhou Z; Zeng X; Peng L; Liu Q
    Front Public Health; 2022; 10():985834. PubMed ID: 36211665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
    Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
    Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
    Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
    Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
    Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
    J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
    Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
    Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
    Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
    Hamilton G; Hochmair MJ
    Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
    [No Abstract]   [Full Text] [Related]  

  • 20. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.
    Pellegrino B; Facchinetti F; Bordi P; Silva M; Gnetti L; Tiseo M
    Clin Lung Cancer; 2018 Mar; 19(2):e151-e161. PubMed ID: 29174221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.